← Back to Stock Screener← Stock Screener

ZYBERNO

Stock Report

Updated Jun 4, 2026

GENFIT S.A. (GNFT)

Healthcare • NASDAQ

$8.60

Professional Investment Analysis

ZYBERNO SCORE →

Is it a great business? Is it getting better?

27.0/100

POOR BUSINESS

GENFIT S.A. (GNFT) scores 27/100 — concerning metrics indicating significant structural or financial risks.

📊 How is the Zyberno Score calculated? +

The Zyberno Score answers one question: "Is this a quality business worth owning?" It's a 0-100 investment grade that evaluates business fundamentals across four critical dimensions, based on principles from Warren Buffett, Benjamin Graham, Peter Lynch, and Charlie Munger.

The 4 Core Categories (25 points each):

1. PROFITABILITY (25 pts)

Metrics: ROE, ROIC, Net Margin, Operating Margin
Thresholds: ROE >20% excellent • ROIC >20% excellent • Net Margin >20% excellent • Operating Margin >25% excellent

2. FINANCIAL STRENGTH (25 pts)

Metrics: Debt-to-Equity, Current Ratio, Interest Coverage, Altman Z-Score
Thresholds: D/E <0.3 excellent • Current Ratio >2.5 excellent • Interest Coverage >10x excellent • Altman Z >3.0 safe

3. CASH FLOW QUALITY (25 pts)

Metrics: Free Cash Flow, OCF vs Net Income, FCF Margin
Thresholds: Positive & growing FCF excellent • OCF/NI >1.2x excellent (cash earnings exceed accounting)

4. GROWTH & CONSISTENCY (25 pts)

Metrics: Revenue Growth, Net Income Growth, FCF Growth, Piotroski F-Score
Thresholds: Growth via log-linear regression • Piotroski 8-9 excellent, 6-7 good

Score Interpretation:

75-100

GREAT BUSINESS

65-74

GOOD BUSINESS

50-64

AVERAGE BUSINESS

30-49

WEAK BUSINESS

0-29

POOR BUSINESS

→ View full GNFT quality analysis & detailed breakdown

VALUATION SIGNAL

MARGIN OF SAFETY

Is this stock cheap or expensive relative to what the business has historically generated for owners?

Margin of Safety unavailable — insufficient data for the owner-earnings DCF.

BRINA GAP ↗

Is the market underestimating or overestimating what this business is capable of going forward?

-33.3%

Market Overestimates

💰 How is Margin of Safety calculated? +

Margin of Safety measures how much discount or premium you're paying relative to a stock's intrinsic value. It's Benjamin Graham's core principle: the larger the margin, the lower your downside risk.

Formula: (Intrinsic Value − Current Price) ÷ Intrinsic Value × 100%

How We Calculate Intrinsic Value (DCF Method):

Step 1: Calculate current Owner Earnings (OCF − Maintenance CapEx)

Step 2: Calculate company-specific growth rate using log-linear regression on 16 quarters of Owner Earnings

Step 3: Project 10 years forward using the calculated growth rate

Step 4: Discount each year's cash flow to present value using 10% discount rate

Step 5: Calculate terminal value using 3% perpetual growth rate

Step 6: Sum all discounted cash flows = Intrinsic Value

What The Percentages Mean:

+50% or more

EXCELLENT — Very undervalued

+25% to +50%

GOOD — Attractive discount

0% to +25%

FAIR — Reasonable value

0% to -25%

CAUTION — Slight premium

-25% or worse

POOR — Overvalued

"Price is what you pay, value is what you get." — Warren Buffett

→ View full GNFT valuation analysis · → View full GNFT Brina Gap analysis

📈 How is Brina Gap calculated? +

Brina Gap measures the difference between the growth a business can fundamentally sustain and the growth the market is already pricing in.

Formula: Fundamental Growth Rate − Market-Implied Growth Rate

The Two Components:

Fundamental Growth Rate = ROIC × Reinvestment Rate

What the business can sustainably grow at based on how much it reinvests and what return it earns on that capital. Grounded in historical financials.

Market-Implied Growth Rate = Reverse DCF

The growth rate the current Enterprise Value implicitly assumes. Calculated by back-solving a 10-year DCF model (10% WACC, 3% terminal growth) until the present value of projected cash flows equals EV.

What The Gap Means:

Gap > +5% Market Underestimates — potential upside

+2% to +5% Slight Underestimate

-2% to +2% Fairly Priced — market consensus matches fundamentals

-5% to -2% Slight Overestimate

Gap < -5% Market Overestimates — price embeds optimism fundamentals don't support

A positive gap (market underestimates) combined with a positive Margin of Safety is the strongest combined signal — the business is both cheap historically and forward economics are stronger than the price suggests.

Critical Financial Health Indicators

Return on Equity (Profitability):CRITICAL (0.0%)

Debt-to-Equity (Solvency Risk):EXCELLENT (0.17x)

Operating Margin (Operational Efficiency):CRITICAL (0.0%)

Return on Capital (Capital Efficiency):CRITICAL (3.5%)

📊 Valuation Trilogy

Three interconnected metrics for complete valuation analysis

Click any metric for full methodology and detailed analysis

Zyberno's Verdict

GENFIT S.A. (GNFT) stock report — Zyberno Score 27/100 (POOR BUSINESS). Full financial analysis on Zyberno.

According to Zyberno's DCF model, GENFIT S.A. (GNFT) shows a Brina Gap of -33.3%, which weakens the case: based on the company's ROIC (3.5%) and reinvestment rate (-30.3%), the business can fundamentally grow at -1.1% — but the current enterprise value implies the market expects 32.2%.

DIVISION I: EXECUTIVE SUMMARY

A. Market Valuation

Market Price & Capitalization (2)

Current Price:8.60

Market Cap:$429.97M

Valuation Multiples (2)

P/B Ratio:5.33x

Peg Ratio:-999.00x

Enterprise Metrics (3)

Enterprise Value:$348.56M

Ev Ebitda Ratio:59.81x

Pfcf Ratio:25.34x

B. Profitability Assessment

Return Metrics (5)

Roic:

3.5%

📊 Click to view full GNFT ROIC analysis →

Reinvestment Rate:-30.3%

Fundamental Growth Rate (g):-1.1%

Market-Implied Growth Rate:32.2%

Brina Gap:

-33.3%

☷ Click to view full GNFT Brina Gap analysis →

Margin Analysis (1)

Ebitda Margin:7.1%

Yield Metrics (2)

Earnings Yield:-$999.00

Dividend Yield:0.0%

C. Log-Linear Regression Growth Trends

D. Financial Stability

Liquidity Ratios (3)

Current Ratio:1.23x

Quick Ratio:1.23x

Cash Ratio:1.09x

Leverage Analysis (3)

Debt To Equity Ttm:0.17x

Debt-to-Equity Ratio:0.17x

Debt To Ebitda:2.37x

Coverage Ratios (2)

Interest Coverage Ratio:0.69x

Times Interest Earned:0.69

Capital Structure (4)

Working Capital:20,498,097.60

Cash And Cash Equivalents:95,233,947.20

Long Term Debt:$13.82M

Net Debt:-$81.41M

DIVISION II: FINANCIAL STATEMENTS ANALYSIS

A. Income Statement Analysis

Revenue Components (2)

$82.60M

Cost Of Revenue Ttm:$0.00

Profitability Breakdown (2)

$0.00$3.82M

Bottom Line Performance (3)

$1.75M

Income Before Tax:$0.00

Ebitda Ttm:5,827,822.00

Operating Expenses (5)

Operating Expenses:0.00

R And D Expense:0.00

Sga Expense:0.00

Income Tax Expense:$395.90K

Interest Expense:5,558,845.60

Expense Ratios (3)

R And D To Revenue Percentage:0.0%

Sga To Revenue Percentage:0.0%

Ebitda Margin:7.1%

B. Balance Sheet Analysis

Asset Composition (5)

Total Assets:$176.32M

Current Assets:$108.02M

Ppe Net:8,843,618.00

Goodwill:0.00

Intangible Assets:$55.89M

Liability Structure (4)

Total Liabilities:95,713,680.00

Current Liabilities:87,518,632.80

Long Term Debt:$13.82M

Short Term Debt:$0.00

Equity & Capital (3)

Equity:$80.60M

Retained Earnings:$0.00

Common Stock:0.00

Working Capital Items (3)

Accounts Receivable:8,807,521.60

Inventory:4,657.60

Accounts Payable:15,646,042.80

Special Items (2)

Contract Liabilities:0.00

Stock Based Compensation:0.00

C. Cash Flow Analysis

Operating Activities (2)

$18.11M$16.97M

Investment Activities (1)

Investing Cash Flow:-$1.21M

Financing Activities (3)

Financing Cash Flow:-$12.31M

Dividends Paid Ttm:0.00

Stock Repurchase:0.00

Capital Transactions (3)

Common Stock Issuance:0.00

Long Term Debt Issuance:$0.00

Long Term Debt Repayments:$0.00

DIVISION III: OPERATIONAL METRICS

A. Per Share Analysis

Earnings Per Share (1)

Earnings Per Share Ttm:$0.04

Revenue & Cash Per Share (2)

Sales Per Share Ttm:1.65

Operating Cash Flow Per Share:$0.36

Book Value & Capital (2)

Book Value Per Share:$1.61

Cash Per Share:1.90

Dividend Policy (1)

Dividend Payout Ratio:-999.00x

B. Operational Efficiency

Asset Utilization (2)

Asset Turnover Ttm:0.47x

Working Capital Turnover Ttm:4.03x

Receivables Management (2)

Receivables Turnover Ttm:9.38x

Days Sales Outstanding Ttm:38.92

Inventory Management (2)

Inventory Turnover Ttm:17,734.75x

Days Inventory Outstanding Ttm:0.02

Payables & Cash Cycle (2)

Days Payable Outstanding:69.14

Cash Conversion Cycle:-30.20

C. Quality & Risk Metrics

Financial Quality Scores (2)

Financial Strength Score:80.00

Quality Score:90.00

Market Metrics (2)

Beta:0.00x

Volatility Category:unknown

DIVISION IV: INVESTMENT ANALYSIS

A. Value Investment Framework

Damodaran Growth Analysis (4)

Reinvestment Rate:-30.3%

Fundamental Growth Rate (g):-1.1%

Market-Implied Growth Rate:32.2%

Brina Gap:

-33.3%

☷ Click to view full GNFT Brina Gap analysis →

B. Log-Linear Regression Growth Analysis

C. Company Profile & Context

Corporate Information (6)

Symbol:GNFT

Company Name:GENFIT S.A.

Sector:Healthcare

Industry:Biological Products, (No Diagnostic Substances)

Exchange:NASDAQ

Country:United States

Market Classification (3)

Market Cap Category:N/A

Price Category:low

Volume Category:N/A

Share Structure (3)

Shares Outstanding:50.00M

Shares Outstanding Basic:0

Shares Outstanding Diluted:0

Data Processing Info (3)

Processing Version:v3.0

Last Updated:2026-06-04 17:46:15 UTC

Data Timestamp:2026-06-04T17:46:15.698545